IPS Pharma, and the National Pharmacy Association, Background and Context

IPS Pharma is a UK specialist pharmacy company and a member of the National Pharmacy Association (NPA). This case raises fundamental concerns about patient safety, equality law, and governance. It also highlights accountability questions for the NPA as the trade body representing IPS.

Patient Safety Breach

IPS Pharma sent the complainant another patient’s prescription in error. This constitutes a direct breach of confidentiality and a serious risk under UK GDPR and healthcare regulations. It also raises questions about the adequacy of IPS’s internal quality controls and safeguarding measures.

Withdrawal of Service

On 20 August 2025, IPS Pharma’s Pharmacy Manager emailed the complainant’s clinic (Curaleaf) to confirm that they would no longer fulfil prescriptions for this patient, citing “continuous complaints” as the justification. The email stated:

“I will no longer be responding to this patient and his continuous list of complaints despite us trying to assist him in every query… We will fulfil this last order but unfortunately will not accept any further prescriptions/orders for this patient. Please do not post us his prescriptions.”

Terminating access to essential medication on the basis of complaints raises profound ethical and legal concerns. It directly contradicts pharmacy duties of care and may engage protections under the Equality Act 2010.

Obstructive Practices

In addition to service withdrawal, IPS Pharma introduced repeated obstacles into the ordering process:

• Unexplained delays to dispensing medication.
• Requests for address confirmation that had never previously been required.
• Unclear communication and inconsistent responses from staff.

These practices created uncertainty and risk for a disabled patient reliant on timely access to prescription medication.

Data Protection Concerns

IPS Pharma’s published privacy policy was last updated in May 2018, raising questions about whether it reflects current obligations under UK GDPR and the Data Protection Act 2018. Combined with the mishandling of correspondence, this creates further doubt about the company’s compliance posture.

NPA Governance and Accountability

IPS Pharma is a member of the National Pharmacy Association. The NPA presents itself as a guardian of compliance and patient trust. Yet while one of its members engaged in service withdrawal and a proven patient safety breach, the NPA failed to engage meaningfully with complaints. Emails raising concerns were ignored, with no confirmation of receipt.

Monitoring data further shows that NPA staff or contractors accessed multiple pages of the advocacy website around 3pm on the same day correspondence was ignored. This selective engagement — reviewing published material while refusing to acknowledge formal emails — reflects poorly on the NPA’s transparency and governance.

At a Glance, Timeline

• IPS Pharma sends another patient’s prescription in error.
• Service user raises concerns; communication becomes obstructive and delayed.
• 20 Aug 2025: Pharmacy Manager emails clinic to refuse all future prescriptions, citing complaints.
• Unnecessary address confirmations and unexplained dispensing delays imposed.
• Privacy policy last updated May 2018, raising compliance questions.
• NPA ignores formal correspondence while actively reviewing advocacy website pages.
• Issues escalated through pre-action correspondence and watchdog monitoring.

Editor: Kieron JH. This record blends IPS Pharma’s direct failures with the NPA’s governance context. Both are accountable in the public interest.